Fatty Liver Disease: Risks, Treatments, and the Role of the Pharmacist

Fatty liver disease affects a growing number of patients, often progressing silently until advanced stages. This episode highlights what pharmacists need to know about recent terminology changes, risk factors, pharmacotherapy updates, and key counseling strategies to support patients. Tune in to sharpen your clinical knowledge and help identify, manage, and educate patients at risk for this increasingly common condition. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Sarah Wheeler, PharmD, BCACP, CDCES Assistant Professor VCU School of Pharmacy CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current terminology, risk factors, and stages associated with fatty liver disease. 2. Identify evidence-based pharmacologic and non-pharmacologic strategies that pharmacists can use to support patients with or at risk for fatty liver disease. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-219-H01-P Initial release date: 6/23/2025 Expiration date: 6/23/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram